Therapeutic advancement of chronic lymphocytic leukemia

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial

(2012) P. Dreger et al.   BLOOD

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

(2012) M. F. M. de Rooij et al.   BLOOD

Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma

(2012) Andres Forero-Torres et al.   CLINICAL CANCER RESEARCH

Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach

(2012) D. M. Stephens et al.   HAEMATOLOGICA

Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration

(2012) J Hoellenriegel et al.   LEUKEMIA

Long-term outcome of pomalidomide therapy in myelofibrosis

(2011) Kebede H. Begna et al.   AMERICAN JOURNAL OF HEMATOLOGY

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

(2011) W. G. Wierda et al.   BLOOD

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

(2011) M. Q. Lacy et al.   BLOOD

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia

(2011) X. C. Badoux et al.   BLOOD

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

(2011) X. C. Badoux et al.   BLOOD

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

(2011) J. Hoellenriegel et al.   BLOOD

An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients

(2011) Agostino Cortelezzi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

(2011) P. C. Amrein et al.   CLINICAL CANCER RESEARCH

A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia

(2011) Craig Reynolds et al.   INVESTIGATIONAL NEW DRUGS

Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712

(2011) Jennifer A. Woyach et al.   JOURNAL OF CLINICAL ONCOLOGY

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP

(2011) Yuan Yuan et al.   Journal of Hematology & Oncology

Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab

(2011) L. Bologna et al.   JOURNAL OF IMMUNOLOGY

The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia

(2011) J Dürig et al.   LEUKEMIA

Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia

(2011) Mark C. Lanasa et al.   LEUKEMIA & LYMPHOMA

Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia

(2011) Regina Pileckyte et al.   LEUKEMIA & LYMPHOMA

The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease

(2011) O. Giles Best et al.   LEUKEMIA & LYMPHOMA

Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia

(2011) Giuseppe Gritti et al.   LEUKEMIA & LYMPHOMA

Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation

(2010) M. Michallet et al.   BLOOD

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia

(2010) S. M. Jaglowski et al.   BLOOD

17-DMAG targets the nuclear factor- B family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition

(2010) E. Hertlein et al.   BLOOD

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

(2010) William G. Wierda et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study)

(2010) Tadeusz Robak et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

(2010) Jiahuai Tan et al.   Journal of Hematology & Oncology

A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia

(2010) Richard R. Furman et al.   LEUKEMIA & LYMPHOMA

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

(2009) J. C. Byrd et al.   BLOOD

Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?

(2009) J. Delgado et al.   BLOOD

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

(2009) B. F. Eichhorst et al.   BLOOD

B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406

(2009) M. P. Quiroga et al.   BLOOD

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

CD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells

(2009) M. S. Hayden-Ledbetter et al.   CLINICAL CANCER RESEARCH

Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease

(2009) Thomas S. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen

(2009) Susan O'Brien et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia

(2009) Wolfgang U. Knauf et al.   JOURNAL OF CLINICAL ONCOLOGY

Update in the management of chronic lymphocytic leukemia

(2009) Kami J Maddocks et al.   Journal of Hematology & Oncology

Mechanism of action of lenalidomide in hematological malignancies

(2009) Venumadhav Kotla et al.   Journal of Hematology & Oncology

Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia

(2009) J E Castro et al.   LEUKEMIA

A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL

(2008) Thomas Decker et al.   ANNALS OF HEMATOLOGY

AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance

(2008) K. Balakrishnan et al.   BLOOD

Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents

(2008) L. M. Leoni et al.   CLINICAL CANCER RESEARCH

Chronic lymphocytic leukaemia

(2008) G Dighiero et al.   LANCET

Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia

(2008) J E Castro et al.   LEUKEMIA